Nanos3, a cancer-germline gene, promotes cell proliferation, migration, chemoresistance, and invasion of human glioblastoma

Fengyu Zhang1†, Ruilai Liu1†, Cheng Liu1, Haishi Zhang2* and Yuan Lu1*

Abstract

Background: Radiotherapy, chemotherapy, and surgery have made crucial strides in glioblastoma treatment, yet they often fail; thus, new treatment and new detection methods are needed. Aberrant expression of Nanos3 has been functionally associated with various cancers. Here, we sought to identify the clinical significance and potential mechanisms of Nanos3 in human glioblastoma.

Methods: Nanos3 expression was studied in nude mouse glioblastoma tissues and glioblastoma cell lines by immunohistochemistry, Western blot, and RT-PCR. Clustered regularly interspaced short palindromic repeats (CRISPR–Cas9) gene editing assay was performed to generate the Nanos3 knockdown glioblastoma cell lines. The effects of Nanos3 on glioblastoma cells proliferation, migration, invasion, chemoresistance, germ cell characteristics, and tumor formation were analyzed by CCK8, transwell, cell survival experiments and alkaline phosphatase staining in vitro and in nude mouse models in vivo. Correlation between the expression of stemness proteins and the expression of Nanos3 was evaluated by Western blot.

Results: We found that Nanos3 was strongly expressed in both glioblastoma cell lines and tissues. Western blot and sequencing assays showed that the Nanos3 knockdown glioblastoma cell lines were established successfully, and we discovered that Nanos3 deletion reduced the proliferation, migration, and invasion of glioblastoma cells in vitro (P < 0.05). Nanos3 knockdown enhanced the sensitivity of glioblastoma cells to doxorubicin (DOX) and temozolomide (TMZ) (P < 0.05), and Nanos3+/− glioblastoma cell lines did not show the characteristics of the germline cells. In addition, Nanos3 deletion inhibited subcutaneous xenograft tumor growth in vivo (P < 0.001). Moreover, the oncosogenesis germline protein levels of CD133, Oct4, Ki67, and Dazl decreased significantly in glioblastoma cells following Nanos3 knockdown.

Conclusions: Both in vitro and in vivo assays suggest that Nanos3, which is a cancer-germline gene, initiates the tumorigenesis of glioblastoma via acquiring the oncosogenesis germline traits. These data demonstrate that ectopic germline traits are necessary for glioblastoma growth.

Keywords: Glioblastoma, Nanos3, Cancer-germline, CRISPR/Cas9, Tumorigenicity

Background

Gliomas, the most common primary brain tumor, are associated with a poor median survival time that barely exceeds 12 months despite the development of new effective treatments [1–3]. The regular care for glioblastoma patients includes surgery followed by radiation and chemotherapy; Dox and TMZ are the conventional...
chimney facilities with a capacity of 10-15 tons/h.

In May 2020, 100-150 tons of chimney facilities were sold to the European market, and 300-350 tons of chimney facilities were exported to South America. The total output value of chimney facilities in the first half of 2020 was 500-550 M. The average profit margin of chimney facilities in the corresponding period was 15-18%. The total sales revenue of chimney facilities in the first half of 2020 was 700-750 M, and the total number of employees in the company was 450-500. The average salary of employees in the company was 8000-8500 RMB. The average number of overtime hours worked by employees in the company in the first half of 2020 was 120-150 hours. The average overtime hours worked by employees in the company in the first half of 2020 was 120-150 hours.
were purchased from Abcam (Cambridge, UK). The Cell Counting Kit-8 (CCK-8) reagent (CK04) was purchased from DOJINDO Molecular Technologies, Inc. (Japan). An Alkaline Phosphatase Stain Kit (SK-5300) was purchased from Vector Laboratories, Inc. (Burlingame, CA, USA). Puromycin dihydrochloride (60210ES25) was purchased from Yeasen Biotech Co., Ltd. (Shanghai, China). Blasticidin S hydrochloride (15205), Doxorubicin hydrochloride (DOX) (D1515), DMH2 (SML 1535), and BMP4 (B2680) were purchased from Sigma Aldrich (St. Louis, MO, USA), and temozolomide (TMZ) was purchased from Merck (T2577, Darmstadt, Germany).

**Immunofluorescence assay**

A172, U251, and LN229 cells were used for immunofluorescence analyses. Cells were seeded at a density of 10,000 cells/cm² on glass coverslips pretreated with 0.1 mg/ml poly-l-lysine (C0313, Beyotime) to promote adherence. After 24 h, the slices were then washed twice with phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde (PFA) for 20 min at room temperature. To stain cytoplasmic markers, slices were permeabilized by incubation with 0.3% Triton-X-100 for 5 min at room temperature. Cells were blocked by incubation with 5% bovine serum albumin (BSA, Sigma, USA) for 1 h at room temperature and then incubated overnight at 4 °C with the primary antibodies. Controls were performed with 5% BSA as the primary antibody. After washing with PBS, the cells were incubated for 1 h at RT with an AlexaFluor 488 anti-rabbit IgG secondary antibody (1:2000; Invitrogen, CA, USA). Cell nuclei were stained with DAPI (0.5 μg/ml; Beyotime, China). Coverslips were examined with an inverted fluorescence microscope (Olympus, Germany). All the antibodies used for immunofluorescence staining are shown above.

**Western blotting**

Total protein was lysed with RIPA lysis buffer (P0013B, Beyotime, China) and phenylmethanesulfonyl fluoride (PMSF, 1 mM, ST506, Beyotime, China) cocktails; then, they were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, UK). The membrane was blocked for 2 h at room temperature and then incubated with primary antibody overnight at 4 °C. The membrane was then incubated with the HRP-conjugated secondary antibody (CST, USA) for 1 h. The immunoconjugates were detected with an enhanced chemiluminescence substrate (Thermo, USA) using a chemiluminescence imaging system (Tanon, Shanghai, China). Band density was analyzed with ImageJ software. The antibodies used for detecting protein expression are shown above.

**Immunohistochemistry**

Tissue samples were fixed in 10% formalin, paraffin-embedded and cut into 3 μm sections, which were mounted on superfrost plus microscope slides and dried at 60 °C for 1 h. Tissues were deparaffinized by incubating in xylene and rehydrated in an ethanol gradient with decreasing amounts of ethanol until the final wash, which was water. Sodium citrate-hydrochloric acid buffer (pH 6.0, C8532, Sigma, USA) was used for antigen retrieval, and a 3% H₂O₂ solution was applied to quench endogenous peroxidase activity. The slides were then blocked in 10% goat serum (ab7481, Abcam, USA) for 1 h. The slides were incubated with the appropriate primary antibodies overnight at 4 °C. After incubation with the primary antibody, all slides were incubated with appropriate HRP secondary antibodies and stained with a DAB kit (ab64238, Abcam, USA) and with hematoxylin solution (MHS1, Sigma, USA). Finally, slides were dehydrated, cleared and mounted with a permanent mounting medium. Images were acquired under a microscope (Leica, Germany).

**RNA isolation and RT-PCR**

Total RNA was extracted with Trizol (15596018, Thermo, USA) according to the manufacturer’s instructions, and the concentration of RNA was detected by a NanoDrop2000 spectrophotometer (Thermo, USA). Total RNA (500 ng) was reverse-transcribed using a PrimeScript™ RT reagent kit (RR036, Takara, Japan). Quantitative RT-PCR was performed using SYBR premix (RR820, Takara, Japan) according to the manufacturer’s instructions. qPCR experiments were run, and the melting curves of the amplified products were used to determine the specificity of amplification. The threshold cycle number for the genes analyzed was normalized to human GAPDH. All reactions were performed in triplicate, and the results were analyzed via the 2−ΔΔCt method. The primers used for detecting gene expression were human Nanos3-F: CATTATTGTAGGGCTAGTGAT; human Nanos3-R: CCGAAACTCTTGTTTGTCT; human GAPDH-F: TGCACCACCACACTGCTTACG; human GAPDH-R: GGCGTGGACTGTGGTGCAG.

**Cell proliferation assay**

GBM cells were seeded in 96-well plates at a density of 1 × 10³ cells per well, and then, they were incubated for 0, 1, 2, 3, 4, 5, 6 and 7 days. Then, 100 μl of reagent comprising 90 μl DMEM and 10 μl of CCK-8 solution was added to each well, and the plates were incubated for 2 h at 37 °C. The absorbance was measured at 450 nm with a microplate reader (Biotek, USA).
Alkaline phosphatase staining
For alkaline phosphatase (AP) staining, GBM WT cells and Nanos3 deletion cells were treated with a VECTASTAIN ABC-AP kit (Vector Laboratories, USA) according to the manufacturer's instruction. After AP staining, 10 microscopic fields (20× magnification) of each treatment were randomly selected, and AP-positive colonies were counted.

CRISPR/Cas9-mediated Nanos3 knockdown
CRISPR/Cas9-mediated Nanos3 Knockdown in GBM cells was carried out following the protocol of Ran et al. [34]. To generate Nanos3-Knockdown cells using CRISPR–Cas9 gene editing, two different short guide RNAs (sgRNAs) against NANOS3 were purchased from Sigma (HS5000010259; HS5000010260). The Nanos3-sgRNA sequence is as follows: GGC GAA GGC TCA GAC TTC CCGG; GTG GAC ATG GAG GGA GAG. CAGG. The Nanos3 gene was cloned into a CRISPR/Cas9 vector: hU6-gRNA-PGK-Puro-T2A-BFP. The lenti-cas9 pSpCas9 (BB)-2A-GFP (PX458) plasmid was a gift from Feng Zhang (Addgene plasmid #48138). Lenti-Cas9 was transfected into 70–80% confluent GBM cells using X-tremeGENE 9 DNA Transfection Reagent (6365787001, Sigma-Aldrich, USA) and lenti-090 and lenti-091. Puromycin selection was performed for 3–5 days with a final concentration of 1 µg/ml, 3 µg/ml and 2 µg/ml in A172, U251, and LN229 cells, respectively; Lenti-Nanos3 sgRNA-treated cells were then seeded, and another 3–5 days of blasticidin selection was performed using a final concentration of 7 µg/ml, 22 µg/ml, 10 µg/ml in A172, U251, and LN229 cells, respectively. Later, a double selection of clones growing in blasticidin-containing medium and expressing Blue Fluorescent Protein (BFP) was performed. Positive clones were isolated and transferred to 6-well plates; finally, the positive clone was verified by sequencing. Nanos3 deletion was further verified by Western blotting of lysate from the stable cells.

In vivo experiments: xenograft model
All animal studies were performed according to the “Guide for the Care and Use of Laboratory Animals” of the National Institutes of Health. GBM cells (1.5 × 10^5) stably expressing Nanos3^+/− and GBM cells expressing Nanos3^+/+ were subcutaneously injected into 4-week-old female BALB/c nude mice (Shanghai Lab. Animal Research Center, China). Tumor growth was assessed by measuring tumor diameters with Vernier calipers once every 6 days. Tumor volumes were calculated according to the equation: tumor volume (mm^3) = (length × width × width)/2. The survival of the remaining mice was assessed via Kaplan–Meier analysis. When the experiments were stopped, experimental animals were sacrificed by carbon dioxide inhalation, and tumors were removed for biochemical (frozen tissue) and histological (paraffin fixed tissue) analyses.

Statistical analysis
Exact representations of error bars are indicated in each figure. All experiments were executed in triplicate unless otherwise specified. Statistical analysis was performed via GraphPad Prism version 6.0 (San Diego, CA, USA). Differences between groups were considered statistically significant when P < 0.05.

Results
Nanos3 expression is upregulated in both glioblastoma cell lines and glioblastoma tissues
To evaluate whether cancer-germline genes are upregulated in human glioblastoma, RT-PCR experiments, Western blot assays and immunohistochemistry staining were performed to detect the expression of germline-associated genes, namely, Nanos3, in human glioblastoma cell lines and glioblastoma tissues (Fig. 1). The glioblastoma tissues were obtained from the implanted tumor xenografts of glioblastoma multiforme (GBM) cells in mice. RT-PCR showed that Nanos3 was generally overexpressed in GBM cells and the mouse glioblastoma tissues (case 1–4) compared with its expression in normal human astrocytes (NHA) cells and the normal mouse brain (Fig. 1a, c). Moreover, compared with NHA cells, the RNA expression of Sox2, Oct4, and Nanog were increased in GBM cells. Western blot data confirmed that Nanos3 was overexpressed in all GBM cell lines and mouse glioblastoma tissues (glioblastoma 1–5) compared.
with NHA cells and normal mouse brains (Fig. 1b, d). Immunohistochemical analysis revealed that Nanos3 was frequently expressed in glioblastoma tissues implanted from the GBM cell lines (A172, U251, and LN229 cells), and the expression of Nanos3 was higher than it was in the normal brain (Fig. 1e). Immunofluorescence indicated that Nanos3 was expressed in the glioblastoma cells, especially in A172 cells, but not expressed in the
NHA cells (Fig. 1f, Additional file 1: Figure S1). Thus, Nanos3 is expressed at high levels in glioblastoma cells and glioblastoma tissues.

CRISPR/Cas9-mediated knockdown of Nanos3 in GBM cell lines
To explore the function of Nanos3 in glioblastoma genesis, we first generated a Nanos3 single knockdown clone in GBM cell lines via the CRISPR/Cas9 system. CRISPR/Cas9 technology has been confirmed to be an effective gene-editing tool that can target an individual gene, cause an in-frame reading error and subsequently induce a transcriptional-level disruption of the gene. Hence, we selected 1 site to target in a Nanos3 exon. Lenti-Nanos3-sgRNA was transfected into A172, U251 and LN229 Nanos3 WT cells, separately, 5 days after lenti-Cas9 to test the efficiency of gene-editing (shown in Fig. 2a). Then, the expression of green and blue fluorescence was observed by fluorescence microscopy to detect the transient transfection rate (figure not shown). Single cells were isolated from pools harvested 5–7 days after transfection following common culture conditions. Western blotting revealed that glioblastoma cells were successfully transfected with cas9 (Fig. 2b), and the cells co-transfected with lenti-Cas9 and lenti-sgRNA had significantly inhibited Nanos3 expression (Fig. 2b). Furthermore, Sanger sequencing was used to determine whether the target gene was edited (Fig. 2c). Finally, the expression of Nanos3 RNA in the Nanos3 deletion cells was also significantly lower than it was in the Nanos3 WT cells (Fig. 2d). For the homozygous mutants, Nanos3−/− could inhibit cell proliferation and could not grow in the culture conditions. All of the deletion cell lines were heterozygous (Nanos3+/-), but the expression of Nanos3 was still reduced at both the protein and RNA levels in these cells (Fig. 2b, d).

Knockdown of Nanos3 inhibits glioblastoma cell growth and migration in vitro
Nanos3 promotes germline cell growth during the development of germine cells, and it plays a crucial role in brain tumor growth in D. melanogaster. To further investigate whether Nanos3 knockdown could inhibit cell proliferation, we performed cell counts with CCK-8 assays. The results of the CCK-8 cell proliferation assays showed that Nanos3 knockdown significantly inhibited the proliferation of A172, U251 and LN229 cells (Fig. 3a), and the proportion of G1 phase cells increased significantly, and that of G2 phase cells decreased in Nanos3 KD cells (Additional file 1: Figure S5). These results indicated that knockdown of Nanos3 could induce the G1 phase cell cycle arrest in GBM cells, and thus Nanos3 affected glioblastoma cells proliferation pattern. Nanos3 deletion also reduced the germline characteristics of the glioblastoma cells, as shown by the AP stain, and loss of germline characteristics might lead the GBM cells to not be easily oncogenic (Fig. 3b, c). Because cell proliferation is directly connected to cell cycle and cyclin D1 acts as a key regulator of the cell cycle [35]. Then we detected whether Nanos3 regulated Cyclin D1 expression using western blot assay, and found that inhibition of Nanos3 reduced the expression of Cyclin D1 (Fig. 3d). To investigate the role of Nanos3 in A172, U251, and LN229 cells in migration, wound healing and transwell migration assays were performed. We found that the number of Nanos3−/− cells was decreased in contrast to the Nanos3 WT cells in migration experiments (Fig. 3e, f). The scratch experiments also revealed that wound recovery was markedly decreased in Nanos3 deletion cell lines, separately, in A172, U251, and LN229 cells (Fig. 3g). These results showed that the silencing of Nanos3 inhibited the migration ability of A172, U251, and LN229 cell lines.

Knockdown of Nanos3 inhibits glioblastoma cell chemoresistance and invasion in vitro
To investigate the fundamental reasons for the chemoresistance to therapy in glioblastoma, we explored whether Nanos3 deletion inhibited the chemoresistance of GBM cells to DOX and TMZ. Upon treatment with DOX and TMZ, we found that knocking-down Nanos3 resulted in significantly lower survival of A172, U251, and LN229 cells (Fig. 4a, b). Together, the assays suggested that Nanos3 may inhibit therapeutic resistance during glioblastoma treatment. To investigate the function of Nanos3 in A172, U251, and LN229 cell invasion, the transwell Matrigel invasion assays were utilized. The transwell invasion assay results showed that fewer Nanos3 knockdown cells had passed through the Matrigel-coated chambers in comparison to WT cells (Fig. 4c, d). These results revealed that the silencing of Nanos3 inhibited the invasiveness of GBM cell lines.

Nanos3 inhibits the formation of glioblastoma via inhibiting the stemness of glioblastoma cells
To test for the function of Nanos3 in vivo, GBM cell lines and Nanos3+/− cells were inoculated subcutaneously into the backs of immunocompromised nude mice. Injection of approximately 10⁵ GBM cells showed a rapid tumor growth in vivo (Fig. 5a, b), whereas no tumor growth was observed in mice injected with Nanos3−/− GBM cells. GBM cells with homogenous Nanos3 deletion were unable to initiate tumorigenesis, and recipient mice...
Fig. 2. CRISPR/Cas9-mediated knockdown of Nanos3 in GBM cell lines. a Lenti-sgRNA against Nanos3 and lenti-Cas9 plasmids were transfected into GBM cell lines (A172, U251, and LN229). A schematic overview of the procedure used for the CRISPR/Cas9 knockdown experiment is shown. b Western blot analysis detected whether cas9 protein was transfected into GBM cells successfully and whether Nanos3 protein was deleted. c The PCR band for the Nanos3-sgRNA infected cells was subcloned and analyzed by sanger sequencing. The sequences of three candidate clones are shown. d RT-PCR assays were utilized to test the RNA expression of the three candidate clones.
remained viable after > 6 months. In this work, to examine whether Nanos3 could participate in the process of stemness and proliferation, we examined the expression of the stem cells markers CD133, Oct4 and Dazl, which are found to be upregulated in GBM cell lines compared to NHA cells in the mRNA level (Fig. 1a, b). BMPs are considered potent inhibitors of glioblastoma during development, and BMP treatment can decrease the tumorigenicity of glioblastoma in vivo [22, 36–38], BMPs negatively regulate stemness and induce differentiation via activation of the Smad signaling cascade [21]. Subsequently, we detected the protein expression of BMP4 and astrocytic differentiation marker glial acidic fibrillary protein (GFAP) using western blot assay, and found that Nanos3 knockdown could increase the protein expression of BMP4 and GFAP, but not the expression of Smad1, which acts in complex with the phosphorylated versions of Smad1, Smad5, and Smad9; then, this complex entered the nucleus to control the transcription of target genes. Blocking the BMP pathway using a BMP receptor kinase inhibitor (DMH2) did not induce Nanos3 to participate in the BMP pathway. In contrast, exogenous activation of BMP signaling using BMP4 did not contribute to the activation of BMP signaling by Nanos3 in the GBM cells (Additional file 1: Figure S3b). We then investigated whether Nanos3 knockdown could affect the stemness and proliferation of glioblastoma. Western blot assays showed that the knockdown of Nanos3 significantly decreased the protein expression of CD133, Oct4, Dazl, and Ki67 in these glioblastoma cell lines but did not alter the expression of β-catenin (Additional file 1: Figure S3a). Therefore, Nanos3 knockdown was found to suppress the oncogenicity of glioblastoma by inhibiting the cancer-germline characteristics and tumor cells growth, and increasing the glioma cells differentiation (Fig. 5c, d).

Discussion
Nanos was originally discovered and researched in Drosophila melanogaster (fruit fly) [39]. The Nanos gene was primarily found to be crucial for anterior–posterior axis polarity, abdomen formation, and germ cell development [39–41]. The RNA-binding protein Nanos3 is highly conserved in the germline stem cell function, were it works with other Nanos orthologs, such as Nanos2 and Nanos3 in Mus musculus [17]. Since Old et al. [11] proposed an embryonic rest theory for the origin of cancer, cancer cells and germ cells have been found to share several characteristics, such as rapid proliferation, migration, and colonization. Nanos genes are responsible for germine traits such as survival, which are also important for tumor cells [42]. There is plentiful evidence for the ectopic activation of germline genes during the progression of several human cancer types [43]. CRISPR/Cas9 technology is a powerful method which was widely used in tumorigenesis [44, 45] and metastasis [46] as well as genes associated with drug response [47–49]. In this work, we built the Nanos3$\pm$ GBM cell lines via CRISPR/Cas9 knockout technology and the Nanos3$^+/-$ GBM cell lines grew stably for generation. Then, we demonstrated that ectopic expression of the germline gene Nanos3 in human glioblastoma brain tumors and its association with tumorigenicity. Moreover, high-level ectopic expression of Nanos3 is an independent marker of overall survival and may therefore be essential for the progression of glioblastoma. Our results confirm this view and show the close similarity between tumor formation and tissue development. Interestingly, Nanos3 is expressed in PGCs at mouse E7.25, and loss of function results in a lack of germ cells and a failure of PGCs fails to migrate into the gonad [17]. Nanos protein expression has also been linked to increased cell migration, invasion and cell survival [16, 50]. We also found that Nanos3 deletion could significantly inhibit glioblastoma cell proliferation, migration, and invasion. These results are consistent with the fact that Nanos3 modulates essential aspects of human germ cell development during the cell cycle [14]. It is worth noting that Nanos3 is strongly expressed in adult germ cells but not in adult somatic tissues, except the brain; however, Nanos3 is ectopically expressed in many human cancers. This expression pattern has been
illustrated by naming these genes ‘cancer-germline’ genes [51, 52], and these findings are in agreement with the previous study of Julaton et al. [14, 16]. In *D. melanogaster*, *Nanos* was found to be one of the crucial germline genes that were upregulated in a brain tumor model [9]. These results demonstrate that Nanos3 may be considered a ‘cancer-germline’ gene involved in the tumorigenicity of glioblastoma.

Glioblastoma, the most common neurological tumor, could be inhibited by BMP treatment. Differentiation-inducing properties of BMPs could inhibit the tumorigenicity of GBM cells, making BMPs promising candidates for GBM therapy [22, 53–55]. In this work, Nanos3 knockdown enhances the protein expression of BMP4, which in turn activates the astrocyte’s fate switch, in agreement with the differentiation potential of BMPs in GBM cells. To further investigate whether Nanos3 enhances the tumorigenicity through BMP/Smads signaling pathway, western blot analysis showed that the presence of BMP4 significantly reduced the expression of Nanos3, and DMH2 could restore the expression level of the Nanos3 in GBM cell lines. p-Smad1/5/9 are the complex proteins in the downstream of BMP signaling pathway. BMP4 could induce small mothers against decapentaplegic 1/5/9 (Smad1/5/9) phosphorylation. It is reported that BMP4 can inhibit the glioblastoma cell growth. A172 could inhibit the protein expression of BMP4 and BMP signaling pathway, but U251 and LN229 could only specifically inhibit the expression of BMP protein, not the entire pathway. These might be related to the different expression of p53 genotype in different GBM cells, since A172 expressed the p53 WT gene, but U251 and LN229 expressed the p53 mutation. Interventions to modulate BMP signaling have the potential to enhance the effect of conventional chemotherapy dependent on the mutational status of p53 [56]. Subsequently, we tested whether Nanos3 could participate in the WNT signaling pathway using western blot assay, and showed that there were no difference in β-Catenin expression (Additional file 1: Figure S3A). It is suggested that Nanos only inhibited stemness gene expression in glioma but did not participate in other signaling pathways to regulate glioma formation. These results suggest that Nanos3 inhibits BMP protein and suppresses the GBM cells differentiation but not participate in the BMP/Smads pathway. Besides, the expression of glioblastoma stem/progenitor cell markers like CD133 and Oct4 have also been widely investigated in vitro and in vivo concerning their tumor-initiating potential, migratory and proliferative capacity and resistance to chemotherapy [29, 57]. Dazl is the maker of the germline cells, nanos3 knockdown could significantly reduce the germline trait. We found that knockdown of Nanos3 significantly reduced GBM cell proliferation, tumorigenicity, and the characteristics of cancer-germline cells. It is speculated that Nanos3 may induce the oncogenesis of glioblastoma via simulating the characteristics of embryonic germ cells. Therefore, *Nanos* gene could represent ideal candidates, since it belongs to a unique group of CG genes that primarily contribute to some key process of tumor development, including unlimited proliferation, metastasis, adaption to cellular energetics constraints, and resistance to apoptosis. The observation that Nanos3 gene exerts oncogenic functions may explain the origin of the tumor cells. Further researches on these CG genes may therefore open the way to the development of highly selective anti-cancer therapies.

**Conclusion**

In summary, our results strongly suggest that Nanos3 may play a crucial role in glioblastoma development and progression. Nanos3, which is a cancer-germline gene, influences glioblastoma progression by enhancing cell proliferation, migration, and invasion. This implies that human cancer-germline genes are suspected to contribute to oncogenesis germline traits such as immortality, migration, invasiveness, and survival, suggesting that Nanos3 may function as an important marker of cancer in the germline and the detection of glioblastoma.
Fig. 5  Nanos3 inhibits the formation of glioblastoma via inhibiting the stemness of glioblastoma cells.  

a The tumor growth sizes were recorded every 6 days between Nanos3 WT and Nanos3+/- GBM cell lines in xenograft tumor models.  
b Tumor growth was observed from GBM cells with Nanos3 alterations that were implanted subcutaneously in nude mice. n = 5; data are shown as the mean ± SE. ***P < 0.001.  
c Western blot analysis of the relative protein levels of CD133, Oct4, Ki67, Dazl, BMP4, and GFAP in Nanos3+/- and WT GBM cells.  
d Quantitative analysis of the relative protein levels of CD133, Oct4, Ki67 and BMP4 in GBM cells was carried out in triplicate. Data are shown as the mean ± SE. *P < 0.05, **P < 0.01, ***P < 0.001
Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s12935-020-01272-1.

Additional file 1: Figure S1. Expression of Nanos3 in glioblastoma cell lines. Figure S2. Colony formation of GBM cells after chemotherapy. Figure S3. The relationship between Nanos3 and BMP pathway. Figure S4. The regulatory relationship between Nanos3 and Dazl. Figure S5. The regulatory relationship between Nanos3 and Dazl. Figure S6. Effect of Nanos3 on glioblastoma cell cycle.

Abbreviations
CG: Cancer-germline; MBT: Malignant brain tumor; PGC: Primordial germ cell; CRISPR: Clustered regularly interspaced short palindromic repeats; sgRNAs: Single guide RNAs; GBM: Glioblastoma multiforme; NIH-A: Normal human astrocytes; AP: Alkaline phosphatase; DOX: Doxorubicin; TMZ: Temozolomide; KD: Knockdown; WT: Wild type; BMP: Bone morphogenetic proteins; PBS: Phosphate-buffered saline; CCX-8: Cell Counting Kit-8; BSA: Bovine serum albumin; RT: Room temperature; BFP: Blue Fluorescent Protein; DMM: Dulbecco’s modified Eagle medium.

Acknowledgements
We would like to thank professor Chunfang Liu for supporting us in the logical thinking and the experiment platform. This work was supported by the National Natural Science Foundation of China (Grant No. 81372141; 81600202). The funding body had no role in the design of the study and collection, analysis and interpretation of data and in writing the manuscript.

Funding
This work was supported by the National Science Foundation of China (No. 81372141 and No. 81600202). The funding body had no role in the design of the study and collection, analysis and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets generated during the current study are applicable.

Ethics approval and consent to participate
All animal studies according to protocols approved by the Laboratory Animal Committee of Fudan University and handled with care and euthanized humanely during the experiment.

Consent for publication
None.

Competing interests
The authors declare that there are no conflicts of interest.

Received: 13 January 2020 Accepted: 16 May 2020
Published online: 26 May 2020

References
1. Zeng T, Cui D, Gao L. Glioma: an overview of current classifications, characteristics, molecular biology and target therapies. Front Biosci (Landmark Ed). 2015;11:1044–15.
2. Le Rhun E, Taillibert S, Chamberlain MC. Anaplastic glioma: current treatment and management. Expert Rev Neurother. 2015;15(6):601–20.
3. Deluche E, Bessette B, Durand S, Gaie F, Rigau V, Robert S, et al. CH3L1, NTRK2, 1p/19q and IDH status predicts prognosis in glioma. Cancers. 2019;11(4):544.
4. Kuo YC, Chang YH, Rajesh R. Targeted delivery of etoposide, camustine and doxorubicin to human glioblastoma cells using methoxy-poly(ethylene glycol)-poly(e-caprolactone) nanoparticles conjugated with wheat germ agglutinin and folic acid. Mater Sci Eng C. Mater Biol Appl. 2019;96:114–28.
5. López-Valero I, Saiz-Ladera C, Torres S, Hernández-Tiedra S, García-Taboada E, Rodríguez-Fomés F, et al. Targeting glioma initiating cells with a combined therapy of cannabinoids and temozolomide. Biochem Pharmacol. 2018;157:266–74.
6. Munksgaard Thørøn M, Chmielarska Masoumi K, Krona C, Huang X, Kundu S, Schmidt L, et al. Integrin α10, a novel therapeutic target in glioblastoma, regulates cell migration, proliferation, and survival. Cancers. 2019;11(4):587.
7. Li XT, Li JC, Feng M, Zhou YY, Du ZW. Novel IncRNA-ZNF281 regulates cell growth, stemness and invasion of glioma stem-like U251s cells. Neoplasma. 2019;66(1):118–27.
8. Zhen Y, Nan Y, Guo S, Zhang L, Li G, Yue S, et al. Knockdown of NEAT1 repressed the malignant progression of glioma through splicing mR-107 and inhibiting CDK14. J Cell Physiol. 2019;234(7):1067–9.
9. Jancic A, Mendizabal L, Llamazares S, Rossell D, Gonzalez C. Ectopic expression of germline genes drives malignant brain tumor growth in Drosophila. Science. 2010;330(6002):1824–7.
10. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615–25.
11. Old LJ. Cancer vaccines: an overview. Cancer Immun. 2008;8(Suppl 1):1.
12. Bonnomet A, Polette M, Strumane K, Gilles D, Dalstein V, Kilezty C, et al. The E-cadherin-repressed bNanos1 gene induces tumor cell invasion by upregulating MT1-MMP expression. Oncogene. 2008;27(26):3692–9.
13. Wang Z, Lin H. Nanos maintains germline stem cell self-renewal by preventing differentiation. Science. 2004;303(5666):2016–9.
14. Julaton VT, Rejo Pera RA. NANSOS function in human germ cell development. Hum Mol Genet. 2011;20(11):2238–50.
15. Sonoda J, Wharton RP. Drosophila brain tumor is a translational suppressor. Genes Dev. 2001;15(6):762–73.
16. Greet S, Andries V, Polette M, Gilles C, Staes K, Martin AP, et al. The human NANSOS gene contributes to lung tumour invasion by inducing epithelial–mesenchymal transition. J Pathol. 2015;237(1):25–37.
17. Tsuda M, Sasaoka Y, Kiso M, Abe K, Haraguchi S, Kobayashi S, et al. Conserved role of nanos proteins in germ cell development. Science. 2003;301(5637):1239–41.
18. Kusz KM, Tomczyk L, Sajek M, Spik A, Latoń-Bielenka A, Jedrzejczak P, et al. The highly conserved NANSO2 protein: testis-specific expression and significance for the human male reproduction. Mol Hum Reprod. 2009;15(3):165–71.
19. Jørgensen A, Nielsen JE, Almstrup K, Toft BG, Petersen BL, Meyts ER-D. Dysregulation of the mitosis-meiosis switch in testicular carcinoma in situ. J Pathol. 2013;229(4):588–98.
20. Miles WO, Korenjak M, Griffiths LM, Dyer MA, Provero P, Dyson NJ. Post-transcriptional gene expression control by NANOS is up-regulated and functionally important in pRb-deficient cells. EMBO J. 2014;33(19):2201–15.
21. Safarí M, Khooshnevisan A. Cancer stem cells and chemoresistance in glioblastoma multiform: a review article. J Stem Cells. 2015;10(4):271–85.
22. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006;444(7120):761–5.
23. Pérez Castillo A, Aguilar-Morante D, Morales-García JA, Dorado J. Cancer stem cells and brain tumors. Clin Transl Oncol. 2008;10(S):262–7.
24. Cheng J-X, Liu B-L, Zhang X. How powerful is CD133 as a cancer stem cell marker in brain tumours? Cancer Treat Rev. 2009;35(5):403–8.
25. Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH, et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell. 2008;13(1):69–80.
26. Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18(8):1127–34.
27. Sedaghat S, Gheytachi E, Asgari M, Roudi R, Keymoosi H, Madjd Z. Expression of cancer stem cell markers OCT4 and CD133 in transition cell carcinomas. Appl Immunohistochem Mol Morphol. 2017;25(3):196–202.
28. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 2000;24(4):372–6.

29. Hattemann K, Flüth C, Engel D, Mehndorff HM, Synowitz M, Mentrlein R, et al. Stem cell markers in glioma progression and recurrence. Int J Oncol. 2016;49(5):1899–900.

30. Du Y. The role and molecular mechanism of DAZL gene in lung cancer. Changsha: Hunan Normal University; 2019.

31. Stefanidis K, Pergialiotis V, Christakis D, Patta J, Stefanidis D, Louradris D. OCT-4 and DAZL expression in precancerous lesions of the human uterine cervix. J Obstet Gynaecol Res. 2015;41(5):763–7.

32. Stefanidis K, Louradris D, Vassiliou L-V, Anastasiadou V, Kiapelkou E, Nikas V, et al. Nevirapine induces growth arrest and premature senescence in human cervical carcinoma cells. Gynecol Oncol. 2008;111(2):344–9.

33. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene. 2004;23(43):7274–82.

34. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281–308.

35. Zhang C, Yang M, Li Y, Tang S, Sun X. FOXA1 is upregulated in glioma and promotes proliferation as well as cell cycle through regulation of cyclin D1 expression. Cancer Manag Res. 2018;10:3283–93.

36. Srikanth M, Kim J, Das S, Kessler JA. BMP signaling induces astrocytic differentiation, decreases oligodendroglial lineage commitment. Brain. 2010;133(7):1961–72.

37. Klose A, Waerzeggers Y, Monfared P, Vukicevic S, Kaijzel EL, Winkeler A, et al. Imaging bone morphogenetic protein 7 induced cell cycle arrest in experimental gliomas. Neoplasia. 2011;13(3):276–85.

38. Gomes WA, Mehler MF, Kessler JA. Transgenic overexpression of BMP4 increases astroglia and decreases oligodendroglial lineage commitment. Dev Biol. 2003;255(1):164–77.

39. Irish V, Lehmann R, Akam M. The Drosophila posterior-group gene nanos functions by repressing hunchback activity. Nature. 1989;338(6217):646–8.

40. Wang C, Lehmann R. Nanos is the localized posterior determinant in germline development in Drosophila. Nature. 1989;338(6217):646–8.

41. Loriot A, Boon T, De Smet C. Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia. Int J Cancer. 2003;105(3):371–6.

42. Rousseaux S, Debernardi A, Jaccquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013;5(186):186ra166.

43. Chirasani SR, Sternjak A, Wend P, Momma S, Campos B, Herrmann IM, Graf D, et al. Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain. 2010;133(7):1961–72.

44. Han K, Jeng EE, Hess GT, Morgens DW, Li A, Bassik MC. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat Biotechnol. 2017;35(5):463–74.

45. Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR–Cas9 screening of protein domains. Nat Biotechnol. 2015;33(6):661–7.

46. Chen S, Sanjana Neville E, Zheng K, Shalem O, Lee K, Shi X, et al. Genome-wide CRISPR screens in a mouse model of tumor growth and metastasis. Cell. 2015;160(6):1246–60.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more: biomedcentral.com/submissions